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Background: Eventual control of HIV/AIDS is believed to be ultimately dependent on a safe, effective and
affordable vaccine. Participation of sub-Saharan Africa in the conduct of HIV trials is crucial as this region still
experiences high HIV incidences. We describe the experience of recruiting and retaining volunteers in the first
HIV vaccine trial (HIVIS03) in Tanzania.
Methods: In this trial enrolled volunteers from amongst Police Officers (POs) in Dar es Salaam were primed
with HIV-1 DNA vaccine at months 0, 1 and 3; and boosted with HIV-1 MVA vaccine at months 9 and 21. A
stepwise education provision/sensitization approach was employed to eventual recruitment. Having identified
a “core” group of POs keen on HIV prevention activities, those interested to participate in the vaccine trial
were invited for a first screening session that comprised of provision of detailed study information and
medical evaluation. In the second screening session results of the initial assessment were provided and those
eligible were assessed for willingness to participate (WTP). Those willing were consented and eventually
randomized into the trial having met the eligibility criteria. Voluntary participation was emphasized throughout.
Results: Out of 408 POs who formed the core group, 364 (89.0%) attended the educational sessions. 263 out of 364
(72.2%) indicated willingness to participate in the HIV vaccine trial. 98% of those indicating WTP attended the
pre-screening workshops. 220 (85.0%) indicated willingness to undergo first screening and 177 POs attended for initial
screenings, of whom 162 (91.5%) underwent both clinical and laboratory screenings. 119 volunteers (73.5%) were
eligible for the study. 79 were randomized into the trial, while 19 did not turn up, the major reason being partner/
family advice. 60 volunteers including 15 females were recruited during a one-year period. All participated in the
planned progress updates workshops. Retention into the schedule was: 98% for the 3 DNA/placebo vaccinations, while
it was 83% and 73% for the first and second MVA/placebo vaccinations respectively.
Conclusion: In this first HIV vaccine trial in Tanzania, we successfully recruited the volunteers and there was no
significant loss to follow up. Close contact and updates on study progress facilitated the observed retention rates.
Trial registration numbers: ISRCTN90053831 and ATMR2009040001075080.Background
Despite multiple preventive measures to control HIV
transmission, the pandemic still claims a substantial
number of lives and causes significant morbidity world-
wide. HIV/AIDS still remains a disease of public health
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children) acquiring HIV infection in 2011 was 1.8 mil-
lion [1.6 million – 2.0 million] [1]. Although the avail-
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with other viral borne diseases of public health import-
ance such as small pox [2].
Participation of sub-Saharan Africa in the conduct of
HIV trials is crucial; since this is the region that is still
affected by high HIV incidence [1]. However, recruit-
ment of volunteers in HIV vaccine trials might be a chal-
lenge due to a number of reasons including the fact that
misconceptions are rampant in such communities [3].
The misconceptions are most likely due to limited over-
all societal knowledge on vaccine trials as well as min-
imal exposure to such trials.
Laboratory reference values adopted from the devel-
oped countries can also be a limiting factor. Recruitment
experiences in Uganda revealed that of the 223 volun-
teers screened, 69 (31%) were excluded due to haemato-
logic abnormalities [4]. If local reference ranges had
been employed, 83% of those screened out due to these
abnormalities could have been included in the study,
drastically reducing workload and cost associated with
the screening process. It was also proposed that toxicity
tables used in vaccine and drug trial safety evaluations
may need adjustment as some clinical reference ranges
determined in the study overlapped with grade 1 and
grade 2 adverse events [4].
Engaging in risky sexual behaviors by the would-be
trial volunteers could be another factor. In South Africa
it was observed that male volunteers engaged more in
risky sexual behaviors than female volunteers that in-
cluded casual multiple sexual partners. This necessitated
more risk-reduction counseling in a population that was
being prepared for participation in early HIV vaccine
trial [5].
There have also been reports documenting the diffi-
culty in recruiting females in HIV vaccine trials despite
the fact that women are the most vulnerable and most
affected by HIV. Reasons cited include fear of acquiring
HIV-infection from the vaccine, testing positive for HIV
antibodies, effect of the vaccine upon future pregnancies,
and being mistakenly viewed as being HIV infected [6].
Challenges in recruiting volunteers are not restricted
to resource-constrained countries, and thus various
strategies have been employed in recruiting volunteers
into HIV vaccine trials. In the UK, the most successful
recruiting strategies for participation in two Phase II
prophylactic HIV vaccine (PHV) trials targeted organiza-
tions dealing with HIV, health or social issues and were
directed to large audiences through the mass media.
However, circulated e-mails and word of mouth were
the most resource-effective approaches. Group discus-
sions and the collection of a pool of potential volunteers
were much less effective than one-to-one discussions
and immediate screening after recruitment. These find-
ings were subsequently utilized in devising keyrecommendations to assist PHV trial teams who were
planning subsequent studies [7].
In Thailand, correlates of being screened and recruited
into a phase I/II preventive HIV-1 vaccine trial included
social demographic variables, motivation for interest in
the trial, and factors related to communication and con-
tact. Participants were recruited at two sites through var-
ied methods. The majority of individuals pre-screened
reported altruistic motives for interest in the trial, and
blood donors emerged as a group that may have been
particularly altruistic. Findings indicated site differences
in attrition during recruitment and screening, but not in
enrollment into the vaccine trial. Blood donation and
willingness to be contacted by phone at home were sig-
nificantly related to making and keeping screening ap-
pointments [8].
Preparations towards HIV vaccine trials in Tanzania
begun in 1989 within the Tanzania and Sweden
(TANSWED) HIV Programme, funded by Sida/SAREC
(Swedish Government’s Research Cooperation with De-
veloping Countries) that included capacity building and
preparation of a potential cohort of Police Officers
(POs). In 2002, a European Union (EU) funded HIV
Vaccine Immunogenicity Study (HIVIS) project was ini-
tiated to develop and try out a candidate HIV-DNA
prime followed by HIV-1 MVA boost vaccine and to
further build capacity in conducting HIV vaccine trials
in Tanzania.
The Phase I/II HIV Vaccine Immunogenicity Study
(HIVIS-03) performed between February 2007 and Feb-
ruary 2010 was the first HIV vaccine trial to be con-
ducted in Dar es Salaam, Tanzania. It was a double
blinded, placebo controlled vaccine trial of a candidate
vaccine consisting of priming with multi-gene, multi-
clade (A, B, C) HIV-1 DNA and boosting with HIV-1
MVA (CRF01 subtypes A, E). The trial enrolled 60 vol-
unteers from the Police Force in Dar es Salaam. The co-
hort was chosen as there had been a prior research
contact, (through a Sida/SAREC funded TANSWED
HIV Programme) with it that led to the establishment of
HIV prevalence and incidence in the Force [9,10]. Add-
itionally, they were chosen by taking advantage of the
fact that Police Officers (POs) were from an organized
institution that would have allowed easier long-term fol-
low up. It has been reported that the vaccine in the
HIVIS-03 trial was safe, and induced broad and potent
immune responses against HIV-1 [11].
We hereby describe our experiences in volunteer
recruitment and their retention in the HIVIS03 trial.Methods
The recruitment process involved multiple educational
sessions at different stages that included the following:
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POs “Core group”
These were conducted between January 2005 and April
2007 at the respective police stations in Dar es Salaam,
Tanzania. The sessions included a briefing of the current
situation and epidemiology of HIV worldwide and in
Tanzania, as well as the magnitude of HIV in the Police
Force in Dar es Salaam from previous research con-
ducted within the Police Force. This was then followed
by general information on basic concepts of HIV vaccine
trials, and the need for participation of resource con-
strained countries. The study research assistants ob-
tained personal contact information of POs who were
willing to be members of the “core group” to actively
participate in anti-HIV activities.Sensitization of the core group members
Police Officers who were interested to be members of
the core group received further educational sessions that
again included a briefing of the current situation and
epidemiology of HIV worldwide and in Tanzania, as well
as in the Police Force in Dar es Salaam. This was then
followed by information on the HIVIS 03 trial including
the inclusion and exclusion criteria, the details of the
vaccines to be administered, the possible adverse reac-
tions, mode of the vaccines administration, study sched-
ule and duration. It was particularly emphasized that
participation in the trial was voluntary. Participants were
given ample time to ask questions, and adequate answers
were provided. The study Research Assistants obtained
personal contact information of the POs who were inter-
ested in further information about the present study.
This information was obtained through a one page sheet
that asked if they were willing to be provided with fur-
ther detailed information on the trial, and if they were
willing to be contacted further, and if so, their names
and contact details.Pre-screening workshops
Police Officers who were interested in further details of
the HIV vaccine trial were thereafter contacted and
invited to one of the eight pre-screening workshops,
conducted between 25th November 2006 and 10th
November 2007, whereby detailed information about the
study was provided. The information included the risk
and benefits of participating in the HIVIS 03 trial and
study related procedures. Following the briefing session,
the study team obtained contact information of the POs
who expressed interests and were willing to undergo
screening. The Police Officers who were interested were
thereafter invited to the clinical trial site at the Muhim-
bili National Hospital (MNH) in Dar es Salaam for
screening.First screening
Screening took place between February and November
2007 at the clinical trial site. Every participant was of-
fered an information sheet that described the study and
related procedures. Information on risk and benefits of
participating was also provided. The participants were
then allowed to ask questions and they were provided
with answers by the study Nurse/Doctor. The partici-
pants were there after requested to sign an informed
consent if they were willing to participate in the trial. All
participants were pre and post-test counseled for HIV
followed by an abbreviated risk-assessment for HIV in-
cluding prior history of sexually transmitted infections
and risky sexual practices.
Thereafter the study medical Doctor took a detailed
history and conducted a clinical examination on the par-
ticipants and the information obtained was documented
in a structured case report form (CRF). The participants
were then asked to provide blood and urine samples for
laboratory screening tests. The laboratory tests included
urinalysis, HIV, syphilis and Hepatitis B surface antigen,
clinical chemistry (bilirubin; total and direct, ALT, cre-
atinine and random blood glucose); hematology (total
white blood cells count, granulocyte count, lymphocyte
count, hemoglobin, and platelet count) and CD4+ and
CD + 8 T-Lymphocyte counts. In addition, all female
volunteers underwent urine pregnancy testing. Labora-
tory reference values for hematology and clinical chem-
istry were initially adopted from the Mbeya Medical
Research Programme (MMRP) [12]. Subsequently these
were modified, especially with fasting blood glucose level
to be based on WHO criteria. Reference values for CD4
count were from the Dar es Salaam population as deter-
mined earlier [13].
Following specimen collection all participants were re-
imbursed for their time and travel to an amount ap-
proved by the ethics committee of Tanzanian Shillings
20,000/=, that was equivalent to about 20 USD. The
participants were then requested to return two weeks
later to attend the second screening visit and receive the
initial screening test results.Second screening
In the second screening visit the participants received
all the laboratory results for specimens collected in the
first visit and again their willingness to proceed with the
trial was assessed. The study Doctor thereafter assessed
for the inclusion and exclusion criteria and all volun-
teers who fulfilled the inclusion criteria for the study,
including not testing HIV-positive, were randomized to
receive either the HIV-1 DNA vaccine or a placebo. The
criteria for inclusion into the trial have been reported
earlier [11].
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pointment dates for their first vaccination (enrolment)
within one month of the initial screening.
Post-enrolment procedures
Enrolled volunteers received 3 HIV-1 DNA or placebo
doses (as priming vaccines) at months 0, 1 and 3, by a
needle less device, Biojector, either intramuscularly or
intradermally. This was followed by boosting with 2
intramuscular injections of HIV-1 MVA-CMDR or pla-
cebo at months 9 and 21.
As per protocol, volunteers had to attend a total of 24
scheduled visits. They were assessed for safety as well as
immunogenicity two weeks after each HIV-1 DNA or
HIV-1 MVA vaccination. These were also performed at
4 and 24 weeks after the HIV-MVA immunizations. De-
tails of the vaccination schedules have been described
earlier [11].
To ensure retention, the study team had close contact
with the volunteers through mobile phone communica-
tions, physical visits to their places of work or domicile
when necessary, as well as holding three monthly meet-
ings with all volunteers where study progress and chal-
lenges were mutually discussed.
Data analysis
Data were analyzed using SPSS version 18.0 software.
Proportions or medians (interquartile range [IQR]) were
calculated. Comparison of proportions was done by
Chi-square or Fisher’s exact test where applicable. A
two-sided p-value of less than 0.05 was considered
statistically significant.
Ethics
The HIVIS-03 study protocol received ethical approvals
from the National Ethics Committee at the National In-
stitute for Medical Research (NIMR) and the local Insti-
tutional Review Board of Muhimbili University of Health
and Allied Sciences (MUHAS). The Tanzania Food and
Drug Authority (TFDA) approved the importation of
both the DNA and MVA vaccines and for their use in
healthy adults in the trial.
All screened volunteers and those randomized into the
trial signed informed consent form after having read
through the study information sheet.
Voluntary participation was emphasized at all levels of
Police Force hierarchy. All volunteers found to have HIV
infection and other medical problems during screening
were referred for appropriate care at the MNH.
Results
Educational sessions, screening and enrolment
A “core-group” of 408 POs interested in the fight against
HIV and AIDS was formed from a repeat HIV incidencestudy supported by Sida/SAREC under the TANSWED
HIV Programme. From these, a total of 346 (84.8%) vol-
unteers participated in the sensitization educational ses-
sions. Of these, 258 (72.8%) attendees were willing to
participate in the vaccine trial and hence were ready to
be offered further study details, and of these 220 (87.3%)
volunteers attended the pre-screening sessions. Further,
177 (80.5%) volunteers were willing and attended the
clinic to be screened, of whom 48 (27.1%) were female.
Fifteen of these were not eligible outright (reasons being
pregnancy, age above 40 years, and desire to have chil-
dren within two years). The remaining 162 were
screened. A summary of volunteers’ participation in the
HIVIS-03 trial is shown in Figure 1 and Table 1.
Of 162 volunteers screened between January 2007 to
November 2007, 79 were found to be eligible and were
subsequently randomized. Volunteers above the age of
40 were screened initially, but following the findings
from a similar trial in Stockholm (HIVIS-01/02) which
showed that those with ages above 40 years had poor
immune responses, the age criterion in Dar es Salaam
was changed to include only those between the ages of
18 and 40 years [14].
A comparison of the baseline socio-demographic char-
acteristics of volunteers who were screened and eventu-
ally enrolled is summarized in Table 2. Of the enrolled
volunteers, 36 (60%) had at least secondary education
and 37 (62%) were not married.
The reasons for ineligibility after screening are shown
in Table 3. Of the 79 volunteers who were eventually
randomized, 19 were exited for various reasons (Table 4).
Seven (36.8%) were female, and 12 (63.2%) were male.
The reasons have been published earlier [3]. In brief, the
main reason for screen out was abnormal laboratory
values during screening which accounted for about 46%
of the reasons for screen out.
The first volunteer was enrolled on 27th February
2007, while the last volunteer was enrolled on the 26th
February 2008. Of the 60 volunteers enrolled into the
study, 15 (25%) were female. The overall median (range)
age of volunteers was 28 (20–47) years. Recruitment up
to the last female volunteer spanned over a period of
12 months.
Retention
The 2nd MVA/Placebo vaccinations began on 3rd
February 2009, and vaccinations were completed in July
2009. Table 4 summarizes the retention of volunteers
into the trial. It has to be appreciated that of the en-
rolled 60 volunteers, 42 (70%) completed the trial with
all the five vaccinations. Noteworthy is the fact that
there was a statistically significant difference in the pro-
portion of female volunteers who continued with the 1st
and 2nd MVA vaccinations as well as those who came
Volunteers who attended the Pre-
screening sessions, n= 258
Volunteers who agreed to undergo 
screening, n= 220
Volunteers who did not agree to 
undergo screening workshops, n= 38
Volunteers who did not show up 
for screening at the clinic 
n= 43
Volunteers who attended for 
screening at the study clinic 
n= 177
Volunteers who were screened
n= 162
Volunteers not screened for not 
meeting the eligibility criteria 
outright, n=15
Volunteers screened, eligible 
and randomized, n=79
Volunteers screened and found not 
to be eligible, n=83 
Volunteers who withdrew 
consent after randomization, n=19
Volunteers enrolled
n= 60
Volunteers who completed the 
trial, n=42 
Figure 1 Flow Chart.
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participants.
A total of 18 volunteers including 10 out of 15 females
were discontinued from further vaccinations at different
stages of the trial due to various reasons. These were ei-
ther investigator initiated (in 11 volunteers), or volunteer
initiated (in 7 volunteers). Reasons for discontinuation
among the 11 volunteers in the first group were: seizure
disorder (1 volunteer), sickle cell disease (1 volunteer),
pregnancy (3 volunteers), hypertension (1 volunteer),
imprisonment (1 volunteer), elevated serum bilirubin
(1volunteer), benign ovarian tumor (1 volunteer), HIV
infection (1 volunteer), and uticaria (1 volunteer). Rea-
sons for the 7 volunteers who withdrew from the studyTable 1 Participation of volunteers in the HIVIS-03 trial
Volunteers who: Males
Attended for Screening 128 (72
Screened with available Lab test results 119 (73
Randomized 57 (72.
Exited after Randomization 12 (63.
Enrolled & received 1st DNA/Placebo vaccination 45 (75%
Screening: Enrolment 2.8:1on their own were: relocation (1 volunteer) and social
reasons (6 volunteers). Hence the most common reasons
for discontinuation were medical, and all such volun-
teers were followed up for safety till the end of the study
in accordance with the study protocol.
Discussion
This study describes the recruitment and retention expe-
riences in the first HIV vaccine trial in Dar es Salaam,
Tanzania. We have shown that with extensive prior in-
teractions and targeted communication, it was possible
to recruit all the required 60 volunteers into a Phase I/II
HIV vaccine trial in a resource constrained setting, and
in an environment with no prior HIV vaccine clinical(%) Females (%) Total (100%)
.3%) 49 (27.7%) 177 (100%)
.5%) 43 (26.5%) 162 (100%)
2%) 22 (27.8%) 79 (100%)
2%) 7 (36.8%) 19 (100%)
) 15 (25%) 60 (100%)
3.3:1 3.0:1
Table 2 Baseline characteristics of the screened Police volunteers
Characteristic Attended for screening Randomized Enrolled
Number 177 79 60
Male : Female 126:51 57:22 45:15
Age Range (years) 20-52 19-47 20-47
Median Age (IQR)* 28(24–35) 26 28 (25–35)
Female 26(22–36) 27.5 25 (23–36)
Male 28 (25–35) 26 28 (25–32)
Education, n (%)
Primary 55 (31.6) 8 16(26.7)
Secondary 98 (56.3) 58 36 (60.0)
Post-secondary 21 (12.1) 13 8 (13.3)
Marital Status, n (%)
Single 105 (60.3) 51 37(61.7)
Married/cohabiting 68 (39.7) 28 23(38.3)
*IQR = interquartile range.
Bakari et al. BMC Public Health 2013, 13:1149 Page 6 of 8
http://www.biomedcentral.com/1471-2458/13/1149trial experience. It certainly was an arduous task that re-
quired a whole year to enroll the sixty volunteers.
Challenges of recruiting volunteers have been reported
in several settings and a number of factors are known to
influence the willingness to participate (WTP) in HIV
vaccine trials. A study in India among men having sex
with men (MSM) concluded that pervasive familial,
community and social-structural factors characteristic of
the Indian socio-cultural context could have been re-
sponsible for complicating the individual-focused ap-
proaches to WTP and thereby constraining the
effectiveness of interventions to support recruitment and
retention in HIV vaccine trials [15]. Other studies have
documented factors such as engaging in risky sexual be-
havior by potential volunteers [5]. On the other hand,
among women, fear of contracting HIV from the vac-
cine, testing positive for HIV, the effect of the vaccineTable 3 Reasons for screen out of volunteers in the HIVIS-
03 trial (n = 83)
Reason *Number %
Abnormal laboratory values 41 46.1
Age above 40 years 10 11.2
Had multiple sexual partners 5 5.6
Elevated Blood Pressure 6 6.7
Parents/relatives do not support participation 7 7.9
Desire for having children in coming 2 years 5 5.6
Pregnancy 4 4.5
Did not show up for results/planned visit 6 6.7
Declined to repeat test 2 2.2
Undecided 2 2.2
Other reasons 10 11.2
*Multiple reasons possible in a single individual.upon future pregnancies and mistakenly viewed as being
HIV infected were regarded as important factors affect-
ing their recruitment [6]. It was not surprising therefore
that in this HIVIS-03 trial, being the first such trial in
the country, recruitment had to take such a long time.
Recruitment of volunteers in this trial involved multi-
level educational approaches that essentially emphasized
the role of communication and engagement with the
community in recruiting volunteers into HIV vaccine tri-
als. This is true in resource limited countries like
Tanzania, but is also important even in a developed
country setting [16]. A survey of individuals from areas
of high poverty and high HIV prevalence in Atlanta
USA that employed multilevel modeling techniques con-
cluded that community-level factors do facilitate partici-
pation in HIV vaccine research independent of both
individual- and social/organizational-level factors [17].
It has to be emphasized that the POs participated in this
trial as individuals, and there was no coercion from police
peers. This fact was emphasized at multiple levels of the
Police hierarchy. The PO’s were chosen based on the fact
that we had a prior HIV research experience with them
whereby we had also shown that the cohort was suitable
for HIV vaccine trials [9]. Additionally we wanted to take
advantage of the fact that volunteers from such an institu-
tionalized organization will facilitate their follow-up. Use
of volunteers from institutionalized organizations for ease
of follow up has been found to be desirable as reported in
Nigeria with University students [18].
Abnormal laboratory values and un-supporting family
members have been the main reasons for ineligibility in
this study. In Kenya it has been reported that over 61%
of the screening exclusions in clinically healthy people
were due to laboratory abnormalities and hence calling
for the generation of laboratory reference ranges from
Table 4 Retention of HIVIS-03 trial volunteers
Volunteers who were: Total Males Females p-value*
n (%) n (%) n (%)
Randomized 79 57 22
Exited after Randomization 19 (24.1%) 12 (21.1%) 7 (31.8%) 0.32
Enrolled 60 45 15
Vaccination Visits
Received 1st DNA/Placebo 60 (100%) 45 (100%) 15 (100%) -
Received 2nd DNA/Placebo 60 (100%) 45 (100%) 15 (100%) -
Received 3rd DNA/Placebo 59 (98.3%) 44 (97.8%) 15 (100%) 0.99
Received 1st MVA/Placebo 50 (83.3%) 41 (91.1%) 9 (60%) 0.02
Received 2nd MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
Safety and Immunogenicity visits
2 weeks post 2nd DNA/Placebo 60 (100%) 45 (100%) 15 (100%) -
2 weeks post 3rd DNA/Placebo 59 (98.3%) 44 (97.8%) 15 (100%) 0.99
2 weeks post 1st MVA/Placebo 50 (83.3%) 41 (91.1%) 9 (60%) 0.02
8 weeks post 1st MVA/Placebo 50 (83.3%) 41 (91.1%) 9 (60%) 0.02
24 weeks post 1st MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
2 weeks post 2nd MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
4 weeks post 2nd MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
24 weeks post 2nd MVA/Placebo 40 (66.7%) 35 (77.8%) 5 (33.3%) 0.002
*p-values from Chi square or Fisher’s exact test.
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clinical trials to avoid unnecessary exclusion of willing
participants and to avoid over-reporting of adverse
events for enrolled participants [19]. In this effort, a
large scale study from multiple sites in Africa showed
that detection of hepatitis B surface antigen was the
commonest laboratory abnormality among potential vol-
unteers for clinical trials [20].
It was a challenge to recruit and retain female volun-
teers in this trial, partly contributed to by the fact that
female Police Officers in the cohort were a minority.
Additionally, the study requirement that a volunteer
should not conceive during the entire study duration
might also have contributed to the dismal recruitment
and retention rates of female volunteers. This is sup-
ported by the observation that a number of female vol-
unteers became pregnant during the study and were
thus unable to complete the study protocol. It follows
that for future trials enrolment of volunteers should ex-
tend beyond this population.
It was of note that 24.1% of volunteers exited after
randomization. The possible reasons for such an event
have been reported elsewhere [3]. As reported earlier,
this calls for expanding the HIV vaccine trial education
to the general population from the onset of the trial
design.The fact that 70% of the enrolled volunteers completed
such a protracted trial is worth reckoning as it implies
that indeed retention was excellent after enrolment. It is
believed that this has been greatly contributed by the
excellent relationship that was built between the partici-
pants and the study staff.
Study limitation
The reported findings relate to a specific trial and a spe-
cific population and hence may not be generalized.
Conclusion
Although this was the first HIV vaccine trial in Tanzania,
we successfully recruited study volunteers into the trial
and there was no significant loss to follow up after re-
cruitment. Close contact and frequent educational ses-
sions to the volunteers with updates on study progress
facilitated the observed retention rates to the vaccination
schedule.
Recommendation
Recruitment and retention of volunteers has been pos-
sible, but it is an effort that calls for extensive educa-
tional sessions and a very close interaction with the
community.
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